BIOLASE REPORTS THIRD QUARTER FINANCIAL RESULTS; COMPANY BENEFITTING FROM STRATEGIC ACTIONS TAKEN TO STREAMLINE OPERATIONS AND GAIN GREATER OPERATIONAL EFFICIENCIES
LAKE FOREST, Calif., Nov. 9, 2023 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced its financial results for the third quarter ended September 30, 2023.
Third Quarter Financial Summary
Total revenue was $10.9 million, below the year-ago revenue, as the current macro-environment is impacting laser system sales
Total consumable sales were $2.9 million, a 10% year-over-year increase as utilization of installed laser systems continues to increase
Gross margin was 34%, a 1,400-basis expansion compared to the year-ago level due to the specific actions taken by the Company to drive toward profitability
Continued operating improvements and efficiencies reduced operating loss by 52% year over year compared to the year-ago quarter
"We are continuing to experience heightened interest in our industry-leading dental lasers; however, the uncertainty caused by the macroeconomic environment is extending our sales cycle," commented John Beaver, President, and Chief Executive Officer of BIOLASE. "We believe there are several factors contributing to the longer decision-making process, including higher interest rates. However, it's critical that we maintain our revenue-generating activities to drive greater awareness and interest in our award-winning lasers so that when we return to a more normalized economic climate, we are ready to capitalize on the significant market opportunity we have in front of us. We remain encouraged that new customer acquisition efforts remain strong and the utilization by our installed base continues to grow, as evidenced by the 10% increase in our consumable sales during the quarter. Additionally, our internal optimization actions over the previous quarters have dramatically improved our operations and are beginning to bear fruit. For example, our acquisition of a trunk fiber supplier has allowed us to supplement third-party key components with our in-house manufactured components, significantly expanding our gross margin. Such efforts to reduce our operating expenses enable us to achieve greater efficiencies and improve overall operating performance. We believe that these initiatives considerably reduced our losses and position us for greater success as the economy strengthens. We believe this winning formula – driving greater adoption of our dental lasers and prudent expense management will allow us to meet our revenue and profitability objectives."
Third Quarter Financial Results
Net revenue for the quarter ended September 30, 2023 was $10.9 million, a decrease of 9% compared to net revenue of $12.0 million for the quarter ended September 30, 2022. U.S. laser revenue was $3.8 million for the quarter ended September 30, 2023, a decrease of 17% compared to U.S. laser revenue of $4.6 million for the quarter ended September 30, 2022. U.S. consumables and other revenue for the quarter ended September 30, 2023, which consists of revenue from consumable products such as disposable tips, increased 22% year over year. International laser revenue was $2.9 million for the quarter ended September 30, 2023, an increase of 5% compared to international laser revenue of $2.8 million for the quarter ended September 30, 2022. International consumables and other revenue for the quarter ended September 30, 2023, which consists of revenue from consumable products such as disposable tips, decreased 16% year over year.
Gross margin for the quarter ended September 30, 2023 was 34% compared to 20% for the quarter ended September 30, 2022. The increase in gross profit as a percentage of revenue reflects improvement from changing to new suppliers, which resulted in lower inventory reserves and warranty expenses, along with the impact of a favorable mix from higher margin consumables sales for the quarter ended September 30, 2023. Total operating expenses were $7.4 million for the quarter ended September 30, 2023, compared to $10.1 million for the quarter ended September 30, 2022, a 26% decrease year over year. Operating loss for the quarter ended September 30, 2023 was $3.7 million, compared to an operating loss of $7.7 million for the quarter ended September 30, 2022, an improvement of 52% year over year.
The Company had cash and cash equivalents of approximately $7.8 million on September 30, 2023.
Net Loss and Adjusted EBITDA
The Non-GAAP Financial Measures at the end of this news release provide the details of the Company's non-GAAP disclosures and the reconciliation of GAAP net loss and net loss per share to the Company's adjusted EBITDA and adjusted EBITDA per share.
Net loss attributable to common stockholders for the quarter ended September 30, 2023 was $4.6 million, or $3.89 per share, compared to a net loss of $8.4 million, or $110.36 per share (as adjusted for the reverse stock split), for the quarter ended September 30, 2022. Adjusted EBITDA for the quarter ended September 30, 2023 was a loss of $3.1 million, or $2.67 per share, compared with an adjusted EBITDA loss of $5.6 million, or $73.99 per share (as adjusted for the reverse stock split), for the quarter ended September 30, 2022.
2023 Full Year Financial Guidance
The Company currently expects full year 2023 revenue to be 1 to 3% higher than full year 2022 revenue. In addition, the Company expects net loss from operations for both the full year 2023 and for the fourth quarter of 2023 to be significantly improved compared to the comparable periods for the prior year.
Conference Call Information
BIOLASE, Inc. will host a conference call today at 4:30 p.m. Eastern Time to discuss its operating results for the third quarter ended September 30, 2023, and to answer questions. To access the live call, dial 1-866-682-6100 (U.S.) or +1 862-298-0702 (International) and ask to join the BIOLASE call.
A live and archived webcast of the conference call will be accessible on the BIOLASE Investor Relations page. In addition, a phone replay will be available approximately two hours following the end of the call, and it will remain available for one week. To access the call replay, dial 1-877-481-4010 or +1 919-882-2331 (International) and enter replay passcode: 49456.
About BIOLASE
BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. BIOLASE's products advance the practice of dentistry and medicine for patients and healthcare professionals. As of December 31, 2022, BIOLASE's proprietary laser products incorporate approximately 259 active patents and 24 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. BIOLASE's innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. From 1998 through December 31, 2022, BIOLASE has sold over 45,500 laser systems in over 80 countries around the world. Laser products under development address BIOLASE's core dental market and other adjacent medical and consumer applications.
BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995, that involve significant risks and uncertainties, including statements, regarding BIOLASE's expected revenue and revenue growth. Forward-looking statements can be identified through the use of words such as "may," "might," "will," "intend," "should," "could," "can," "would," "continue," "expect," "believe," "anticipate," "estimate," "predict," "outlook," "potential," "plan," "seek," and similar expressions and variations or the negatives of these terms or other comparable terminology. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE's current expectations and speak only as of the date of this release. Actual results may differ materially from BIOLASE's current expectations depending upon a number of factors. These factors include, among others, adverse changes in general economic and market conditions, competitive factors including, but not limited to, pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business, substantial doubt regarding BIOLASE's ability to continue as a going concern, inability to raise additional capital on terms acceptable to BIOLASE and those other risks and uncertainties that are described in the "Risk Factors" section of BIOLASE's most recent annual report on Form 10-K and quarterly report on Form 10-Q filed with the Securities and Exchange Commission. Except as required by law, BIOLASE does not undertake any responsibility to revise or update any forward-looking statements.
For further information, please contact:
EVC Group LLC
Michael Polyviou / Todd Kehrli
(732) 933-2754
mpolyviou@evcgroup.com / tkehrli@evcgroup.com
BIOLASE, INC. | ||||||||||||||||
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS | ||||||||||||||||
(Unaudited, in thousands, except per share data) | ||||||||||||||||
Three Months Ended | Nine Months Ended | |||||||||||||||
September 30, | September 30, | |||||||||||||||
2023 | 2022 | 2023 | 2022 | |||||||||||||
Net revenue | $ | 10,921 | $ | 12,010 | $ | 35,674 | $ | 34,411 | ||||||||
Cost of revenue | 7,175 | 9,565 | 22,474 | 22,096 | ||||||||||||
Gross profit | 3,746 | 2,445 | 13,200 | 12,315 | ||||||||||||
Operating expenses: | ||||||||||||||||
Sales and marketing | 3,402 | 5,008 | 14,214 | 15,224 | ||||||||||||
General and administrative | 2,679 | 3,109 | 7,495 | 8,825 | ||||||||||||
Engineering and development | 1,362 | 1,979 | 4,352 | 5,177 | ||||||||||||
Total operating expenses | 7,443 | 10,096 | 26,061 | 29,226 | ||||||||||||
Loss from operations | (3,697) | (7,651) | (12,861) | (16,911) | ||||||||||||
Loss on foreign currency transactions | (307) | (329) | (522) | (552) | ||||||||||||
Interest expense, net | (598) | (424) | (1,758) | (1,287) | ||||||||||||
Other income (expenses), net | 28 | — | (119) | — | ||||||||||||
Non-operating loss, net | (877) | (753) | (2,399) | (1,839) | ||||||||||||
Loss before income tax (provision) benefit | (4,574) | (8,404) | (15,260) | (18,750) | ||||||||||||
Income tax (provision) benefit | (15) | 17 | (46) | (23) | ||||||||||||
Net loss | (4,589) | (8,387) | (15,306) | (18,773) | ||||||||||||
Other comprehensive loss items: | ||||||||||||||||
Foreign currency translation adjustments | (105) | (152) | 14 | (415) | ||||||||||||
Comprehensive loss | $ | (4,694) | $ | (8,539) | $ | (15,292) | $ | (19,188) | ||||||||
Net loss | $ | (4,589) | $ | (8,387) | $ | (15,306) | $ | (18,773) | ||||||||
Deemed dividend on convertible preferred stock | — | — | — | (217) | ||||||||||||
Net loss attributable to common stockholders | $ | (4,589) | $ | (8,387) | $ | (15,306) | $ | (18,990) | ||||||||
Net loss per share attributable to common stockholders: | ||||||||||||||||
Basic and Diluted | $ | (3.89) | $ | (110.36) | $ | (22.28) | $ | (287.73) | ||||||||
Shares used in the calculation of net loss per share: | ||||||||||||||||
Basic and Diluted | 1,179 | 76 | 687 | 66 | ||||||||||||
BIOLASE, INC. | ||||||||
CONSOLIDATED BALANCE SHEETS | ||||||||
(Unaudited, in thousands, except per share data) | ||||||||
September 30, | December 31, | |||||||
2023 | 2022 | |||||||
(Unaudited) | (Audited) | |||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 7,809 | $ | 4,181 | ||||
Accounts receivable, less allowance of $2,201 and $2,164 as of September 30, 2023 and | 4,388 | 5,841 | ||||||
Inventory | 13,824 | 15,884 | ||||||
Prepaid expenses and other current assets | 1,761 | 3,053 | ||||||
Total current assets | 27,782 | 28,959 | ||||||
Property, plant, and equipment, net | 6,049 | 4,278 | ||||||
Goodwill | 2,926 | 2,926 | ||||||
Right-of-use assets, leases | 1,718 | 1,768 | ||||||
Other assets | 270 | 255 | ||||||
Total assets | $ | 38,745 | $ | 38,186 | ||||
LIABILITIES, CONVERTIBLE REDEEMABLE PREFERRED STOCK AND | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 7,178 | $ | 5,786 | ||||
Accrued liabilities | 7,613 | 9,210 | ||||||
Deferred revenue, current portion | 2,191 | 2,111 | ||||||
Current portion of term loans, net of discount | 2,800 | 700 | ||||||
Total current liabilities | 19,782 | 17,807 | ||||||
Deferred revenue | 236 | 418 | ||||||
Warranty accrual | 463 | 360 | ||||||
Non-current term loans, net of discount | 11,307 | 13,091 | ||||||
Non-current operating lease liability | 995 | 1,259 | ||||||
Other liabilities | 78 | 362 | ||||||
Total liabilities | 32,861 | 33,297 | ||||||
Series H Convertible Preferred stock, par value $0.001 per share | 300 | — | ||||||
Series J Convertible Preferred stock, par value $0.001 per share | 5,252 | — | ||||||
Total mezzanine equity | 5,552 | — | ||||||
Stockholders' equity: | ||||||||
Common stock, par value $0.001 per share | 2 | — | ||||||
Additional paid-in capital | 312,523 | 301,790 | ||||||
Accumulated other comprehensive loss | (719) | (733) | ||||||
Accumulated deficit | (311,474) | (296,168) | ||||||
Total stockholders' equity | 332 | 4,889 | ||||||
Total liabilities, convertible redeemable preferred stock and | $ | 38,745 | $ | 38,186 | ||||
BIOLASE, INC. | ||||||||
CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||
(Unaudited, in thousands) | ||||||||
Nine Months Ended | ||||||||
September 30, | ||||||||
2023 | 2022 | |||||||
Cash Flows from Operating Activities: | ||||||||
Net loss | $ | (15,306) | $ | (18,773) | ||||
Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities: | ||||||||
Depreciation | 2,133 | 369 | ||||||
Provision for bad debts | 60 | 56 | ||||||
Provision for inventory excess and obsolescence | — | 245 | ||||||
Inventory write-offs and disposals | — | 1,486 | ||||||
Amortization of debt issuance costs | 320 | 197 | ||||||
Change in fair value of warrants | (104) | — | ||||||
Issuance costs for warrants | 447 | — | ||||||
Stock-based compensation | 1,050 | 1,691 | ||||||
Changes in operating assets and liabilities: | ||||||||
Accounts receivable | 1,393 | (664) | ||||||
Inventory | (720) | (5,229) | ||||||
Prepaid expenses and other current assets | 1,322 | (850) | ||||||
Accounts payable and accrued liabilities | (2,301) | 664 | ||||||
Deferred revenue | (102) | (371) | ||||||
Net cash and cash equivalents used in operating activities | (11,808) | (21,179) | ||||||
Cash Flows from Investing Activities: | ||||||||
Purchases of property, plant, and equipment | (1,126) | (3,256) | ||||||
Net cash and cash equivalents used in investing activities | (1,126) | (3,256) | ||||||
Cash Flows from Financing Activities: | ||||||||
Proceeds from the sale of common stock and pre-funded warrants, net of fees | 8,503 | 5,635 | ||||||
Proceeds from the sale of Convertible Preferred Stock, net of fees | 5,490 | — | ||||||
Proceeds from the sale of warrants, net of fees | 1,743 | — | ||||||
Principal payment on loan | — | (1,000) | ||||||
Proceeds from the exercise of common stock warrants | 114 | — | ||||||
Proceeds from the exercise of preferred share warrants | 699 | — | ||||||
Net cash and cash equivalents provided by financing activities | 16,549 | 4,635 | ||||||
Effect of exchange rate changes | 13 | (415) | ||||||
Increase (decrease) in cash, cash equivalents and restricted cash | 3,628 | (20,215) | ||||||
Cash, cash equivalents and restricted cash, beginning of period | 4,181 | 30,175 | ||||||
Cash and cash equivalents, end of period | $ | 7,809 | $ | 9,960 | ||||
Supplemental cash flow disclosure: | ||||||||
Cash paid for interest | $ | 1,419 | $ | 1,110 | ||||
Cash received for interest | $ | 7 | $ | 23 | ||||
Cash paid for income taxes | $ | 12 | $ | 39 | ||||
Cash paid for operating leases | $ | 230 | $ | 219 | ||||
Non-cash right-of-use assets obtained in exchange for lease obligation | $ | 483 | $ | 562 | ||||
Deemed dividend on preferred stock | $ | — | $ | 217 | ||||
Common stock issued upon exercise of preferred stock | $ | 18,503 | $ | — | ||||
Non-GAAP Financial Measures
In addition to the financial information prepared in conformity with generally accepted accounting principles in the U.S. ("GAAP"), this press release includes certain historical non-GAAP financial information. Management believes that these non-GAAP financial measures assist investors in making comparisons of period-to-period operating results and that, in some respects, these non-GAAP financial measures are more indicative of the Company's ongoing core operating performance than their GAAP equivalents.
Adjusted EBITDA is defined as net loss before interest, taxes, depreciation, stock-based and other non-cash compensation, severance expense, change in allowance for doubtful accounts, increase in inventory reserves, and other (income) expense, net. Management uses adjusted EBITDA in its evaluation of the Company's core results of operations and trends between fiscal periods and believes that these measures are important components of its internal performance measurement process. Therefore, investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. Further, the non-GAAP financial measures presented by the Company may be different from similarly named non-GAAP financial measures used by other companies.
BIOLASE, INC. | ||||||||||||||||
Reconciliation of GAAP Net Loss to Adjusted EBITDA and | ||||||||||||||||
GAAP Net Loss Per Share to Adjusted EBITDA Per Share | ||||||||||||||||
(Unaudited, in thousands, except per share data) | ||||||||||||||||
Three Months Ended | Nine Months Ended | |||||||||||||||
September 30, | September 30, | |||||||||||||||
2023 | 2022 | 2023 | 2022 | |||||||||||||
GAAP net loss attributable to common stockholders | $ | (4,589) | $ | (8,387) | $ | (15,306) | $ | (18,990) | ||||||||
Deemed dividend on convertible preferred stock | — | — | — | 217 | ||||||||||||
GAAP net loss | $ | (4,589) | $ | (8,387) | $ | (15,306) | $ | (18,773) | ||||||||
Adjustments: | ||||||||||||||||
Interest expense, net | 598 | 424 | 1,758 | 1,287 | ||||||||||||
Income tax (provision) benefit | 15 | (17) | 46 | 23 | ||||||||||||
Depreciation | 560 | 122 | 2,133 | 369 | ||||||||||||
Severance expense | 1 | — | 230 | — | ||||||||||||
Change in allowance for doubtful accounts | 18 | (87) | 60 | 56 | ||||||||||||
Stock-based and other non-cash compensation | 276 | 591 | 1,050 | 1,691 | ||||||||||||
Increase in inventory reserves | — | 1,731 | — | 1,731 | ||||||||||||
Other (income) expense, net | (28) | — | 119 | — | ||||||||||||
Adjusted EBITDA | $ | (3,149) | $ | (5,623) | $ | (9,910) | $ | (13,616) | ||||||||
GAAP net loss attributable to common stockholders | $ | (3.89) | $ | (110.36) | $ | (22.28) | $ | (287.73) | ||||||||
Deemed dividend on convertible preferred stock | — | — | — | 3.29 | ||||||||||||
GAAP net loss per share, basic and diluted | $ | (3.89) | $ | (110.36) | $ | (22.28) | $ | (284.44) | ||||||||
Adjustments: | ||||||||||||||||
Interest expense, net | 0.51 | 5.58 | 2.56 | 19.50 | ||||||||||||
Income tax (provision) benefit | 0.01 | (0.22) | 0.07 | 0.35 | ||||||||||||
Depreciation | 0.47 | 1.61 | 3.10 | 5.59 | ||||||||||||
Severance expense | — | — | 0.33 | — | ||||||||||||
Change in allowance for doubtful accounts | 0.02 | (1.14) | 0.09 | 0.85 | ||||||||||||
Stock-based and other non-cash compensation | 0.23 | 7.78 | 1.53 | 25.62 | ||||||||||||
Increase in inventory reserves | — | 22.76 | — | 26.23 | ||||||||||||
Other (income) expense, net | (0.02) | — | 0.17 | — | ||||||||||||
Adjusted EBITDA per share, basic and diluted | $ | (2.67) | $ | (73.99) | $ | (14.43) | $ | (206.30) | ||||||||
Other (income) expense, net for the three and nine months ended September 30, 2023 relates to issuance costs from the May 2023 public offering that were allocated to the Series H warrants, and issuance costs from the September 2023 public offering that were allocated to the Series J warrants and immediately expensed due to the liability classification of the warrants. These expenses were partially offset by gains recorded on the revaluation of these warrants during the periods.
View original content to download multimedia:https://www.prnewswire.com/news-releases/biolase-reports-third-quarter-financial-results-company-benefitting-from-strategic-actions-taken-to-streamline-operations-and-gain-greater-operational-efficiencies-301983980.html
SOURCE BIOLASE, Inc.
